August 3, 2017
uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership...
July 31, 2017
uniQure N.V. entered an agreement with Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene...
July 11, 2017
uniQure N.V. presented new clinical data from the ongoing Phase I-II trial of AMT-060.
April 25, 2017
uniQure announced their gene therapy AMT-060, received PRIME designation from the European Medicines Agency.